Biologics Development in Immunology and Inflammation — Featuring Amir Reichman, CEO of Scinai Immunotherapeutics

This episode features an interview with Amir Reichman, CEO of Scinai Immunotherapeutics, a biopharma company focused on developing, manufacturing and commercializing cutting-edge biological treatments within the inflammation and immunology (I&I) sector, with a primary focus on addressing autoimmune and infectious diseases. Scinai Immunotherapeutics is working on developing nanosized antibodies from alpacas, known as VHH-antibodies or NanoAbs, which show promise as improved biological therapies for various illnesses. These NanoAbs are being tailored to treat conditions with significant unmet medical requirements and promising market prospects, including psoriasis and asthma. Prior to being appointed as Scinai’s CEO in 2021, Mr. Reichman recently held the position of Head of Global Vaccines Engineering Core Technologies and Asset Management at the GSK Vaccines headquarters in Belgium. Before that, he was the Senior Director of the Global GSK Vaccines Supply Chain. He became part of GSK in 2015 following its acquisition of Novartis Vaccines, where he had various leadership positions with growing responsibilities within the Global Vaccines Supply Chain Management team, based in Holly Springs, NC, USA. Tune into the episode to hear more about the development of new, cutting-edge inflammation and immunology therapies. Mr. Reichman also shares insights into the most significant trends currently shaping the inflammation and immunology sector. For more life science and medical device content, visit the Xtalks Vitals homepage. Follow Us on Social Media Twitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured